ADXS-503

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameADXS-503
Drug Alias NameADXS-503
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAyala Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesOS Therapies IncAyala Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A